STAT’s First Opinion platform features articles by biotech insiders, healthcare workers, and researchers discussing topics in the life sciences. The platform also publishes Letters to the Editor to facilitate discussion around these articles. Authors like Fred D. Ledley argue that the pharmaceutical industry can create affordable products without compromising profits, while others like Kim Meyers criticize Trump’s “Right to Try” policy. Ezekiel J. Emanuel and John Connolly praise Mark Cuban’s efforts to address drug shortages, and Juliana M. Reed calls for reform of pharmacy benefit managers to improve access to affordable biosimilars for patients with gastrointestinal diseases.
Source link
Readers sound off on right to try falsehoods, pharma execs, more
